Accueil   Diary - News   All news Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes

Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes

ADOCIA-HOMELyon, France, September 20, 2016 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today the initiation of a Phase 1b clinical trial evaluating BioChaperone® Combo, its proprietary formulation combining insulin analog glargine (Lantus®, Sanofi), the gold-standard of long acting insulin, and the fast-acting insulin analog, insulin lispro (Humalog®, Eli Lilly and Company). BioChaperone® technology enables this combination by solubilizing insulin glargine at neutral pH, at which it is compatible with fast-acting insulin analogs.

 

 

 

Read the press release